I. Treatment with 2 mg. of a non-growth-promoting bovine diabetogenic peptide or growth hormone I in two divided doses, one at tbe beginning and one 7-9 hours later, to hypobhysectomized rats during a 24-hour fast maintained their muscle glycogen at a normal level.
(x954). Russell and Wilhelmi (1950) have also demonstrated that purified growth hormone exerts the ' glycostatic effect '.
The present work indicates that another diabetogenic peptide, distinct from growth hormone, also exerts the glycostatic effect.
MATERIALS AND METHODS
Hypophysectomized and normal male rats of the Sprague-Dawley strain have been used for studies of the glycostatic effect and were obtained fmm Simonsen Labs Inc., Gilroy, California. Hormone Assay Laboratory, Chicago, provided the hypophygectomized male rats used for tibia tests. The hypophysectomized rats were obtained 5 days postoperatively and were maintained on a rat pellet diet. Complete atrophy of the gonads and accessory organs was accepted as indicating complete removal of the anterior lobe. Studies TUTWILJSR AND LOUIS IT&. J. Biochem.
were carried out between 2 weeks and 2 months weighed, and frozen. The liver sections and after hypophysectomy. No differences were observed in the responses of animals studied soon gastrocnemii were then placed in I j-ml. centrifuge previously (Louis and others, I 966). The purified diabetogenic polypeptide preparation was obtained by further purification of the material on Sephadex G-loo (Tutwiler and Louis, 1970) . The diabetogenic activity of this material was demonstrated in dogs. The peptide was plepared for injection in the same way as that previously described (Louis and others, 1963).
Bovine growth hormone (NIH-GH-B8) was dissolved in 0.9 per cent NaCl, with the addition of a small amount of o-1 N NaOH. The bovine serum albumin employed was dissolved in 0'9 per cent NaCl.
The experimental animals were given saline, bovine serum albumin, bovine growth hormone, or our diabetogenic polypeptide preparations intraperitoneally in 2 equal doses, I at the beginning of the n4-hour fasting period and the second 7-9 hours later. The volume of solution injected per dose was 0-5-1.0 ml.
At the end of the z4-hour experimental period, the animals were sacrificed by decapitation. The whole livers were removed and 2 separate pieces (approximately I g.) were weighed and immediately frozen. The z gastrocnemii were removed,
RESULTS
The values obtained for muscle and liver glycogen and for blood-glucose of normal and hypophysectomized rats are summarized in Tuble I. Hypophysectomized rats fasted for 24 hours and given saline injections showed an abnormal decrease in blood glucose and muscle glycogen when compared with fasted intact rats. The liver glycogen of hypophysectomized rats was only slightly less than that of intact rats fasted 24 hours. These results are similar tq those reported by Russell and Bennett (1937) .
The effects of treating hypophysectomized rats with bovine serum albumin, bovine growth hormone, and our diabetogenic polypeptide are summarized in Table ZZ . It is apparent that 2 mg. of bovine growth hormone or 2 mg. of bovine diabetogenic polypeptide were sufficient to maintain their 32' muscle glycogen at normal levels.
In an Table 111 shows the minimum effective dose attempt to show that the effects of these two (total amount given during the fast that can hormones were not non-specific effects of prevent depletion of liver and muscle njected protein, bovine serum albumin and glycogen) of the purified diabetogenic polyan inactivated form of our peptide (precipipeptide in fasted hypophysectomized rats. tated at PH I .g-2.0) were used as controls.
The minimum effective dose under the conIt is clear that these compounds are incapable ditions described above is 0.2-0.3 mg. per of maintaining muscle glycogen in hypophyrat. This is similar to the minimum effective sectomized rats during a 24-hour fast.
dose of purified growth hormone as shown bovine growth hormone (Table 111 ) confirm operated preparation. those findings. In addition, however, they Table V demonstrates that 1000 pg. of our diabetogenic polypeptide are not growthpromoting when measured according to the tibia test of Greenspan and others (1949) .
DISCUSSION
The control data (Table I ) of the present experiments confirm previous reports that (I) well-fed hypoph~ectomized rats maintain demonstrate that our diabetogenic polypeptide from bovine adenohypophysis is potent with respect to this ' glycostatic effect '. Our results indicate, too, that adrenal cortical function is not essential for the maintenance of muscle glycogen by our diabetogenic polypeptide, a phenomenon previously documented for pituitary extracts (Bennett, 1938; Bennett and Perkins, 1945) .
Because of the similarity in the ' glycostatic effects ' of bovine growth hormone and our diabetogenic polypeptide, we have compared the growth-promoting activity of these two substances as measured in the tibia test of Greenspan and others ( 1949)) 
CONCLUSION
The diabetogenic polypeptide reported by our laboratory to be present in the urine of patients with lipoatrophic diabetes, diabetic patients with proteinuria, and, subsequently, to be present in bovine, ovine, and porcine adenohypophysis, has now been demonstrated to exert a glycostatic effect in fasting hypophysectomized rats. While pharmacologically similar to growth hormone in several respects, the diabetogenic peptide possesses no growth-promoting activity and differs from growth hormone on a physicochemical basis. Since it is unlikely that this peptide represents an altered growth hormone molecule, it is possible that this polypeptide, rather than growth hormone, may be implicated in the pathogenesis of diabetes mellitus and for its complications in man.
